176 related articles for article (PubMed ID: 17931087)
1. Pharmacogenetics of acute lymphoblastic leukemia treatment response.
Cunningham L; Aplenc R
Expert Opin Pharmacother; 2007 Oct; 8(15):2519-31. PubMed ID: 17931087
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenetic considerations for acute lymphoblastic leukemia therapies.
Dulucq S; Laverdière C; Sinnett D; Krajinovic M
Expert Opin Drug Metab Toxicol; 2014 May; 10(5):699-719. PubMed ID: 24673379
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenetics in acute lymphoblastic leukemia.
Cheok MH; Pottier N; Kager L; Evans WE
Semin Hematol; 2009 Jan; 46(1):39-51. PubMed ID: 19100367
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenomics of acute leukemia.
Ansari M; Krajinovic M
Pharmacogenomics; 2007 Jul; 8(7):817-34. PubMed ID: 18240908
[TBL] [Abstract][Full Text] [Related]
5. Pharmacogenomics of childhood acute lymphoblastic leukemia.
Brenner TL; Pui CH; Evan WE
Curr Opin Mol Ther; 2001 Dec; 3(6):567-78. PubMed ID: 11804271
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenetics influence treatment efficacy in childhood acute lymphoblastic leukemia.
Davidsen ML; Dalhoff K; Schmiegelow K
J Pediatr Hematol Oncol; 2008 Nov; 30(11):831-49. PubMed ID: 18989161
[TBL] [Abstract][Full Text] [Related]
7. Role of miRNAs in treatment response and toxicity of childhood acute lymphoblastic leukemia.
Umerez M; Garcia-Obregon S; Martin-Guerrero I; Astigarraga I; Gutierrez-Camino A; Garcia-Orad A
Pharmacogenomics; 2018 Mar; 19(4):361-373. PubMed ID: 29469670
[TBL] [Abstract][Full Text] [Related]
8. Pharmacogenetic Predictors of Treatment-Related Toxicity Among Children With Acute Lymphoblastic Leukemia.
Maxwell RR; Cole PD
Curr Hematol Malig Rep; 2017 Jun; 12(3):176-186. PubMed ID: 28317081
[TBL] [Abstract][Full Text] [Related]
9. Role of pharmacogenomics and pharmacodynamics in the treatment of acute lymphoblastic leukaemia.
Pui CH; Relling MV; Evans WE
Best Pract Res Clin Haematol; 2002 Dec; 15(4):741-56. PubMed ID: 12617874
[TBL] [Abstract][Full Text] [Related]
10. Pharmacogenomics of acute lymphoid leukemia: new insights into treatment toxicity and efficacy.
Relling MV; Ramsey LB
Hematology Am Soc Hematol Educ Program; 2013; 2013():126-30. PubMed ID: 24319173
[TBL] [Abstract][Full Text] [Related]
11. Pharmacogenomic effects on therapy for acute lymphoblastic leukemia in children.
Wall AM; Rubnitz JE
Pharmacogenomics J; 2003; 3(3):128-35. PubMed ID: 12815362
[No Abstract] [Full Text] [Related]
12. Pharmacogenetic determinants of outcome in acute lymphoblastic leukaemia.
Aplenc R; Lange B
Br J Haematol; 2004 May; 125(4):421-34. PubMed ID: 15142113
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenetics of childhood acute lymphoblastic leukemia.
Lopez-Lopez E; Gutierrez-Camino A; Bilbao-Aldaiturriaga N; Pombar-Gomez M; Martin-Guerrero I; Garcia-Orad A
Pharmacogenomics; 2014 Jul; 15(10):1383-98. PubMed ID: 25155938
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenetics of outcome in children with acute lymphoblastic leukemia.
Rocha JC; Cheng C; Liu W; Kishi S; Das S; Cook EH; Sandlund JT; Rubnitz J; Ribeiro R; Campana D; Pui CH; Evans WE; Relling MV
Blood; 2005 Jun; 105(12):4752-8. PubMed ID: 15713801
[TBL] [Abstract][Full Text] [Related]
15. Childhood acute lymphoblastic leukemia: update on prognostic factors.
Vrooman LM; Silverman LB
Curr Opin Pediatr; 2009 Feb; 21(1):1-8. PubMed ID: 19242236
[TBL] [Abstract][Full Text] [Related]
16. Pharmacogenomics of acute lymphoblastic leukemia.
Kager L; Evans WE
Curr Opin Hematol; 2006 Jul; 13(4):260-5. PubMed ID: 16755223
[TBL] [Abstract][Full Text] [Related]
17. Review of pharmacogenetics studies of L-asparaginase hypersensitivity in acute lymphoblastic leukemia points to variants in the GRIA1 gene.
Lopez-Santillan M; Iparraguirre L; Martin-Guerrero I; Gutierrez-Camino A; Garcia-Orad A
Drug Metab Pers Ther; 2017 Mar; 32(1):1-9. PubMed ID: 28259867
[TBL] [Abstract][Full Text] [Related]
18. The influence of polymorphisms in the drug transporter, ABCB1 on the toxicity of glucocorticoids in Saudi children with acute lymphoblastic leukaemia.
ElFayoumi RI; Hagras MM; Abozenadaha A; Gari M; Abosoudah I; Shinawi T; Mirza T; Bawazir W
Pharmacol Rep; 2019 Feb; 71(1):90-95. PubMed ID: 30508724
[TBL] [Abstract][Full Text] [Related]
19. Acute lymphoblastic leukaemia: a model for the pharmacogenomics of cancer therapy.
Cheok MH; Evans WE
Nat Rev Cancer; 2006 Feb; 6(2):117-29. PubMed ID: 16491071
[TBL] [Abstract][Full Text] [Related]
20. Genomic strategies to improve outcome and individualize therapy in cancer: the paradigm of childhood acute lymphoblastic leukemia.
Kager L
J BUON; 2009 Sep; 14 Suppl 1():S181-6. PubMed ID: 19785064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
